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ABSTRACT 
Objective: The objective of the present study was to investigate the possibility of obtaining a controlled, relatively constant effective level of 
lamivudine microspheres.  
Methods: Lamivudine loaded sodium alginate (SA) and tamarind mucilage(TM) mucoadhesive microspheres were prepared by ionic gelation 
technique with three different proportions of SA and TM with different concentrations of CaCl
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. The prepared microspheres were evaluated for 
drug loading, particle size distribution, surface morphology, FTIR, in vitro wash off, in vitro release and stability studies.  
Results: The microspheres were found to be free flowing having diameter ranging from 769.22 to 978.56 µm, drug encapsulation efficiency (DEE) 
was found to be 65.28 to 92.33%. Percent drug release after 12 h were ranging from 85±1.51 to 97±1.44. In vitro release profile of all formulations 
shows slow controlled release up to 12 h. In vitro wash off studies shown fairly good mucoadhesivity with 20% microspheres adhered after 6h. 
Stability studies showed that no significant change in particle size and maximum DEE in comparison to the formulation stored at room temperature.  
Results: The lamivudine loaded SA-TM mucoadhesive microspheres can be conveniently prepared which showed better result and it may be used 
full for controlling the drug release and improve the bioavailability. 




Oral drug delivery systems continue to be the most accepted and 
popular one among all the drug delivery systems as it offers several 
advantages over the conventional drug delivery systems like 
improving patient’s compliance and convenience due to the 
reduction of frequency of administration [1]. The formulation of 
controlled drug delivery systems is important to achieve better 
clinical efficacy and patient compliance [2], Such systems are highly 
desirable for drugs that have a short half-life to avoid unnecessary 
side effects, burst effect or overdose [3, 4]. In addition, controlled 
release dosage forms ensure optimum and uniform supply of the 
drug, reduce the frequency of intakes [5, 6], enhance stability [7] and 
increase absorption of some drugs [8]. 
Microspheres possess important features among the controlled drug 
delivery systems by virtue of their small size and efficient carrier 
characteristics [9], but the success of dosage form is limited due to 
its residence time. Hence mucoadhesive microsphere drug delivery 
systems are used to extend the residence time at the site of 
application, maintain therapeutically effective plasma drug 
concentration levels for a longer duration, reducing the dosing 
frequency and minimize fluctuations in the plasma drug 
concentration at the steady state in the controlled and reproducible 
manner [10-12]. 
Recently, the mucoadhesive polymers have drawn great interest in 
the designing of oral drug delivery systems to prolong the gastric 
residence time for the dosage forms as well as to facilitate the 
intimate contact with an underlying absorptive surface to enhance 
the oral bioavailability of drugs [13, 14].  
Amongst various natural polymers, alginates have been found 
extensively used, as the matrix in various drug delivery applications 
due to its hydrogel-forming properties [15]. Alginates are 
polysaccharides obtained from marine brown algae (Laminaria 
hyperborean, Ascophullumnodosum, Macrocystispyriferaetc.) [16], 
which are the monovalent form of alginic acid belonging to the 
family of linear copolymers, composed of two monomeric units, β-D-
mannuronic acid (M) and α-L-guluronic acid (G). These residues are 
arranged in homopolymeric blocks (GG and MM) and 
heteropolymeric blocks (MG) [17]. Alginates undergo ionotropic 
gelation in aqueous solution in the presence of divalent cations like 
Ca2+, Ba2+, Pb2+, Cu2+, Cd2+, Zn2+, and the like and trivalent cation like 
Al3+, 
Lamivudine is an anti-retroviral agent which is chemically 
designated as 4-amino-1-[(2R, 5S)-2-(hydromethyl)-1,3-oxathiolan-
5-yl]-1,2-dihydropyrimidin-2-one, used in the treatment of HIV [27]. 
Lamivudine (3-TC), 2-deoxy-3-thiacytidine, is a potent nucleoside 
analog reverse transcriptase inhibitor with very low cellular 
cytotoxicity. Moreover, lamivudine is active against zidovudine-
resistant human immunodeficiency virus (HIV) [28, 29]. Lamivudine 
has approximately 80% oral bioavailability in human with the usual 
dosage of 150 mg twice daily in combination with other 
antiretroviral agents [30]. Conventional oral formulations of 
lamivudine are administered multiple times a day because of its 
due to the ionic interaction and intermolecular bonding 
between the carboxylic acid groups located on the polymer 
backbone and cations [18]. Though alginates have mucoadhesive 
property, but, the cross-linked alginate beads are usually fragile [19, 
20]. Therefore, to overcome this fragile character, blending of 
different mucoadhesive polymers is done. Blending with suitable 
polymers may improve the drug encapsulation efficiency (DEE), 
which is usually lower in only alginate microspheres prepared by 
ionotropic gelation method. 
One cheap and naturally derived polymer is tamarind mucilage (TM) 
obtained from the seeds of Tamarindus indica L., a common tree of 
India and South East Asia. Tamarind is composed of (1 → 4)-β-D-
glucan backbone substituted with side chains of α-D-xylopyranose 
and β-D-galactopyranosyl (1 → 2)-α-D-xylopyranose linked (1 → 6) 
to glucose residues [21, 22]. It is used as a binder, gelling, thickening, 
emulsifying, and suspending agent in different pharmaceutical 
formulations and acts as a stabilizer in food and pharmaceutical 
industries [23, 24]. Tamarind mucilage has been described as a 
viscosity enhancer showing mucomimetic, and mucoadhesive 
property [25]. Again, due to its hydrophilic and mucoadhesive 
property, it finds its use in the development of mucoadhesive drug 
delivery systems [26]. 
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moderate half-life (5-7 h) [31]. Treatment of HIV using conventional 
formulations of lamivudine is found to have many drawbacks, such 
as drug accumulation due to frequent dosing, plasma concentration 
fluctuation, poor patient compliance, and high cost [32]. 
Incorporation of lamivudine in controlled release or sustained 
release dosage forms such as mucoadhesive microspheres may 
control its absorption from the gastrointestinal tract and overcome 
the variability problems. Therefore, an attempt to prepare, TM 
blending with SA to produce microspheres, which facilitate an 
intimate contact with the mucous membranes (i.e., mucoadhesion or 
bioadhesion), and thus the release of lamivudine at a controlled rate 
over an extended period to maximize the therapeutic effect is made. 
The objectives of the investigation were to isolate TM from the seeds 
of Tamarindus indica L. seeds, to prepare, evaluate and characterize 
SA-TM mucoadhesive microspheres by ionotropic gelation 
technique. 
MATERIALS AND METHODS 
Materials 
The pure drug Lamivudine was obtained by Hetero Drugs Pvt ltd, 
Hyderabad (Telangana, India). Sodium alginate and Calcium chloride 
were procured from yarrow chemicals and SD fine chemicals 
Mumbai respectively. Tamarind seeds were procured from the local 
market. All other reagents used were of analytical grades and double 
distilled water was used throughout the studies. 
Method 
Isolation of tamarind mucilage 
Raw seeds of tamarind seeds (Tamarindusindica L.) were cleaned 
with distilled water to remove any extra pulp. Two hundred fifty 
grams of cleaned seeds were broken into small pieces and grounded 
into fine powder. Powders were taken in a 1000 ml beaker loaded 
500 ml water and boiled on water bath at 80–100 °C with a constant 
stirring till a viscous solution was obtained and kept aside for 2 h for 
the release of mucilage, then filtered. The filtrate was precipitated 
out with ethanol in crude form. The precipitated material was 
filtered through a muslin bag into conical flask and marc is squeezed 
well in order to remove the mucilage completely, in between hot 
distilled water (25 ml) was added through the sides of muslin bag. 
The aqueous filtrate is concentrated to 1/3rd of its volume. The 
obtained precipitate is settled by keeping in a refrigerator for 
overnight. After complete settling of the precipitate, it was filtered 
and dried the residue at 37 °C. The obtained dried powder was 
reduced to a fine powder and passes through 120# and subjected for 
identification test to confirm its identity. The prepared TM powder 
was stored in desiccators for further study [33-35]. 
Formulation of microspheres 
Lamivudine loaded SA-TM mucoadhesive microspheres were 
formulated by using the ionic-gelation technique. Polymer SA was 
dissolved in distilled water to form a homogenous solution. A 
homogenous solution of TM was prepared by dissolving in distilled 
water in a separate beaker. Both the polymer solution and mucilage 
mixed, to this core material, lamivudine was added and mixed 
thoroughly. The proportion of drug to polymer was maintained 1:1 
in all formulations. The resulting mixture was then added as a thin 
stream using 21 gauze needles into 100 ml CaCl2 solution. The thin 
stream droplets were retained in the CaCl2 
Formulation code 
solution for 15 min to 
complete the curing reaction and to produce rigid spheres. The 
microspheres were collected by filtration and washed repeatedly 
with water. The obtained microspheres were then air-dried and 
stored for further characterization [36]. Formulation was shown in 
table 1. 
 
Table 1: Formulation and processing parameters of lamivudine based SA-TM mucoadhesive microspheres 
SA: TM CaCl2 DEE (%) PS* * 
FT-1 1:1 5 65.28±3.81 978.56±12.58 
FT-2 1:1 7.5 73.85±2.66 928.21±15.68 
FT-3 2:1 10 79.96±4.06 873.13±16.26 
FT-4 2:1 5 70.65±3.95 919.24±19.47 
FT-5 2:1 7.5 78.35±3.26 874.48±15.12 
FT-6 2:1 10 86.35±3.98 823.47±13.28 
FT-7 3:1 5 77.86±4.17 851.28±14.54 
FT-8 3:1 7.5 85.89±3.68 806.53±18.65 




Yield of microspheres 
All the batches of dried microspheres were accurately weighed 
separately and percentage yield is calculated by using the given equation.  
Avg of three determinations, SA-Sodium Alginate; TM-Tamarind Mucilage; DEE-Drug Encapsulation efficiency; PS-Particle Size 
Percentage yeild = Practical weight
Theoretical weight(polymer+drug)
× 100 
Determination of DEE (%) 
Accurately weighed, 100 mg of microspheres were taken and 
crushed using pestle and mortar. The crushed powders of drug-
loaded microspheres were placed in 500 ml of phosphate buffer pH 
7.4 and kept for 24 h with occasional shaking at 37±0.5 °C.  
After the stipulated time, polymer debris formed after the 
disintegration of microspheres was removed by filtration. The drug 
content in the filtrate was determined using a UV-VIS 
spectrophotometer (Shimadzu, Japan) at 271 nm [37]. The DEE of 
microspheres was calculated using the following formula:  
 
Encapsulation effeciency =
Actual amount of drug encapsulated
Theoretical drug content
× 100 
Drug-excipients interaction studies 
Assessment of possible incompatibilities between a pure drug 
substance, polymer and mucilage forms an important part of the 
development of dosage form. Samples were reduced to powder and 
analysed with KBr pellets by using a Fourier transform infrared 
(FTIR) spectroscope (Perkin Elmer Spectrum). The pellet was placed 
in the sample holder and spectral scanning was taken in the 
wavelength region ranging between 4000 and 400 cm−1 at a 
resolution of 4 cm-1
Where, X
 with a scan speed of 1 cm/sec [38]. 
Particle size (sieving methods) determination 
This test was performed with the help of sieves of different size. They 
were arranged in sieve shaker in such a way that the coarsest sieve on 
top and the finer sieves at the bottom. Microspheres were placed on the 
top and run the machine to segregate, the weight of the microspheres 
remain on the sieves were collected and weighed [39]. The sizes of the 
microspheres were determined by carrying out studies in triplicate and 





i-Mean size range;  
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Surface morphology studies 
The external morphology of the microspheres was studied using 
scanning electron microscopy (SEM). Mucoadhesive microspheres of 
lamivudine loaded SA-TM were fixed on aluminium studs and coated 
with gold using a sputter coater SC 502, under vacuum [0.1 mm Hg] 
and are analyzed using-Model JSM-840 A, Joel. Japan. The samples 
were then randomly scanned, and photomicrographs were taken 
[40]. 
In vitro wash off test for mucoadhesion 
The mucoadhesivity of lamivudine loaded SA-TM mucoadhesive 
microspheres were evaluated by in vitro wash-off method. Freshly 
excised pieces of goat intestinal mucosa (2 × 2 cm) (collected from 
the slaughterhouse) were mounted on a glass slide (7.5 × 2.5 cm) 
using cyanoacrylate glue. About 50 microspheres were spread onto 
the wet tissue specimen, and the prepared slide was hung onto a 
groove of the disintegration test apparatus. The tissue specimen was 
given a regular up and down movement at 37±0.5 °C loaded 900 ml 
of phosphate buffer (pH 7.4). After regular time intervals, the 
machine was stopped and the number of microspheres still adhering 
to the tissue was counted [41]. 
Stability studies 
All the formulations were studied for stability profile at 40 °C±2 
°C/75%±5% RH for 6 mo (Climatic zone IV condition for accelerated 
testing) to assess their stability. The protocol of stability studies was 
in compliance with the WHO recommended ICH guidelines for 
stability testing intended for the global market. After intervals of 30, 
60, 90, 120 and 180 d, samples were withdrawn and retested for 
DEE (Drug Content) and Particle size [42]. 
In vitro drug release studies 
To study the in vitro dissolution profile, microspheres equivalent to 
50 mg of lamivudine were filled in hard gelatin capsules. Dissolution 
studies were performed using the dissolution test apparatus USP-II 
with paddle (Electrolab, Mumbai, India). The phosphate buffer pH 
7.4 (900 ml) was used as dissolution medium at 37±1 °C. The paddle 
was rotated at 50 rpm. The 5 ml of samples were withdrawn on 
definite time intervals using pipette and immediately replaced with 
an equal quantity of phosphate buffer pH 7.4. The amount of drug 
released was determined using (collected aliquots were filtered and 
suitably diluted) UV-VIS spectrophotometer (Shimadzu, Japan) at 
271 nm against a blank (phosphate buffer, pH 7.4). In order to 
predict and correlate the in vitro release behaviour of lamivudine 
from SA-TM mucoadhesive microspheres and marketed tablet 
Lamivir, data were fitted into a suitable mathematical model. The 
studies were carried out in triplicate. The in vitro dissolution data 
were tabulated and computed by using dissolution software viz., PCP 
DISSO V3.0.  
-Percentage microspheres retained on the smaller sieve range. 
RESULTS AND DISCUSSION 
Isolation of tamarind mucilage and preparation of lamivudine 
loaded SA-TM mucoadhesive microspheres 
Mucilage was isolated from tamarind seeds (Tamarindusindica L.) 
and the average yield of mucilage was found to be 16.32% w/w. The 
lamivudine loaded different ratio of isolated TM and SA blend (1:1, 
1:2 and 1:3) with different concentrations of CaCl2
The DEE in lamivudine loaded SA-TM mucoadhesive microspheres 
were within the range between 65.28±3.14 and 92.33±3.93 % w/w 
(table 1). The higher DEE in lamivudine loaded SA-TM 
mucoadhesive microspheres was seen in formulation FT9, where TM 
to SA blend ratio as 1:3 and the concentration of cross-linking 
material, CaCl
 (5-10%) as cross-
linking material by ionotropic gelation method were prepared, as 
formulation shown in table 1. Rigid and discrete lamivudine loaded 
SA-TM mucoadhesive microspheres were obtained when dispersion 
mixture of SA, TM and core material lamivudine added in a solution 
containing calcium ions.  
Encapsulation efficiency 
2 was 10 % w/v. The DEE was increased with 
decreasing TM to SA blend ratios and increasing cross-linking 
concentrations. This may be due to the high degree of cross-linking 
as the amount of SA in the polymer blend, and concentration of 
crosslinking material (i.e. CaCl2) solution was increased [43].  
When drug-loaded polymer blend (SA-TM) was added into a 
solution of CaCl2, the calcium ions replaces the sodium ions of SA to 
form calcium alginate, which provides cross-linking to form the 
cross-linked microspheres. Again, at a lower concentration of CaCl2, 
the microspheres might have larger pores due to insufficient cross-
linking that resulted in lower drug encapsulation [44]. 
Particle size and surface morphological characteristics 
The particle size of lamivudine loaded SA-TM microspheres for each 
formulation was carried out by sieve analysis method. The 
diameters of these microspheres were within the size range of 
769.22±7.42 to 978.49±18.72 μm (table 1). Increases in the 
diameter of these microspheres were found with the increasing 
proportion of TM into formulations. This is may be due to the 
increase in viscosity of polymer blend solution with the 
incorporation of TM in an increasing ratio that in turn increased the 
size of the droplet. Again, the reduction in the size of the particle of 
these formulated SA-TM mucoadhesive microspheres was observed 
when there is an increase in the concentration of CaCl2in solution. 
This may due to shrinkage of the polymeric gel by a higher degree of 
cross-linking with the high concentration of crosslinker (i.e. CaCl2
 
Fig. 1: SEM photograph of lamivudine loaded SA-TM 
mucoadhesive microsphere 
 
FTIR spectroscopic analysis 
) 
[45]. It was also observed that the DEE of lamivudine loaded SA-TM 
mucoadhesive microspheres were appeared to decrease with 
increasing diameter. The morphological analysis of microspheres 
was done by SEM and presented in fig. 1. The SEM photograph 
indicated that microspheres were spherical particles of rough 
surfaces with no tendency to aggregate. Their surface morphologies 
appeared to have a rough surface with characteristic pores, large 
wrinkles, and cracks. These pores, cracks, and wrinkles may be due 
to polymeric gel collapsing during the drying process of 
microspheres. 
 
FTIR spectrometric analysis was performed to confirm the 
compatibility of lamivudine with polymers used to prepare 
microspheres formulation. The FTIR spectra of lamivudine, SA, TM, 
and lamivudine loaded SA-TM mucoadhesive microspheres were 
shown in fig. 2. In the FTIR spectra of lamivudine loaded SA-TM 
mucoadhesive microspheres, various characteristic peaks of sodium 
alginate, tamarind, and lamivudine were appeared without any 
significant shifting of peaks. Suggesting, there were no interactions 
between the lamivudine and the polymers (TM, and SA) used. 
Gada et al. 




Fig. 2: FTIR spectra of A) Pure drug lamivudine, B) SA, C) TM and D) Lamivudine loaded SA-TM mucoadhesive microspheres 
 
In vitro drug release 
Lamivudine release from various SA-TM microspheres was studied 
in simulated intestinal pH (phosphate buffer, pH 7.4). Various 
lamivudine loaded SA-TM microspheres showed the controlled 
release of lamivudine over 12 h. The lamivudine release from SA-TM 
microspheres was slow and dependent on both the proportion of the 
polymer (TM, and SA) and the percentage of cross-linking agent 
CaCl2.  The release of lamivudine from SA-TM mucoadhesive 
microspheres was observed85.16±1.51 to 97.37±2.44inphosphate 
buffer, pH 7.4 after 12 h (fig. 3). It can be observed that 
comparatively higher proportion of TM in formulations, the more 
hydrophilic property of the TM combined better with water to form 
a viscous gel structure, which might blockade the pores on the 
surface of microspheres and controlled the release profile of the 
drug, lamivudine. Also, the release of lamivudine from SA-TM 
microspheres formulated with a higher concentration of CaCl2 
comparatively controlled than the microspheres prepared with a 
lower concentration of CaCl2 
Mucoadhesive (in vitro wash-off test) 
[46]. 
The in vitro wash-off test to know mucoadhesivity of these SA-TM 
microspheres loaded lamivudine was carried out at simulated 
intestinal pH (phosphate buffer, pH 7.4) for 6 h. The percentage of 
microspheres adhering to the goat intestinal mucosal tissue varied 
from 15.55±0.58 to 19.60±3.25% in phosphate buffer after 6h (fig. 
4). The results of the wash-off test indicated that the lamivudine 




Fig. 3: In vitro dissolution profile of lamivudine loaded SA-TM mucoadhesive microspheres and lamivir tab 
 
Stability studies 
The stability study of the microspheres was carried out at 
accelerated temperatures. The percentage of drug content was 
estimated as a part of storage stability studies considering initial 
drug content as 100%. The thermal degradation of optimized 
formulation were studied by keeping the formulations at accelerated 
temperatures of 40 °C ±2 °C/75% RH ±5% RH. The physical 
observations of samples, particle size, DEE given in table2 and 3. The 
product retained its spherical geometry and did not show shrivelling 
tendency during the 6-month storage period. The results of the 
stability studies indicated that the lamivudine contaminating SA-TM 
microspheres were stable at all conditions but most stable at room 
temperature.
Gada et al. 
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Fig. 4: In vitro wash off test to know mucoadhesiveness of lamivudine loaded SA-TM microspheres 
 
Table 2: Stability study of particle size for optimized batches of lamivudine loaded SA-TM mucoadhesive microspheres 
Formulation code Parameter Observation during accelerated stability studies* 
Particle Size Initial 3 Mo 6 Mo 
FT-3 873.13±16.26 878.05±15.91 879.23±13.85 
FT-6 823.47±13.28 831.24±12.67 831.68±14.25 
FT-9 769.22±10.19 776.35±16.38 780.35±11.98 
*Avg of three determinations 
 
Table 3: Stability study of DEE for optimized batches of lamivudine-containing SA-TM mucoadhesive microspheres 
Formulation code Parameter Observation during accelerated stability studies* 
DEE Initial 3 Mo 6 Mo 
FT-3 79.96±4.06 79.02±3.86 78.05±2.67 
FT-6 86.35±3.98 85.92±2.94 84.83±3.89 
FT-9 92.33±4.42 91.12±4.08 90.73±2.96 
*Avg of three determinations 
 
CONCLUSION 
The lamivudine loaded SA-TM mucoadhesive microspheres by 
ionotropic gelation technique was developed and evaluated. The DEE of 
these microspheres were within the range. The prepared microspheres 
were of spherical shape with rough surfaces, and their average particle 
size varied with coat ratio and calcium chloride concentration FTIR 
analysis suggested that there were no interactions between the 
lamivudine and the polymers (TM, and SA) used. All these SA-TM 
mucoadhesive microspheres exhibited fairly good mucoadhesivity. The 
method of preparation for SA-TM mucoadhesive microspheres for oral 
lamivudine delivery was found to be very simple and reproducible. 
Finally, it can be said that this lamivudine loaded SA-TM mucoadhesive 
microspheres are very much suitable for controlled systemic 
administration of lamivudine through controlled drug release, increase 
bioavailability their by improving patient compliance. 
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